Compare Stocks: ATNM, PMN, CBUS, and INO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATNM Actinium Pharmaceuticals	$1.01 +1.0%	$0.94	$0.74 ▼ $1.80	$31.76M	0.01	147,467 shs	111,591 shs
CBUS Cibus	$1.65 -1.2%	$1.73	$1.09 ▼ $4.19	$126.11M	1.61	433,459 shs	89,727 shs
INO Inovio Pharmaceuticals	$1.29 +2.4%	$1.05	$0.56 ▼ $2.98	$133.38M	1.52	2.54 million shs	1.70 million shs
PMN Promis Neurosciences	$13.78 -1.5%	$13.56	$6.27 ▼ $27.40	$123.58M	-0.23	105,299 shs	51,475 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATNM Actinium Pharmaceuticals	-0.99%	-10.71%	+15.41%	-20.63%	-43.18%
CBUS Cibus	-0.60%	-1.76%	-13.92%	+15.97%	+26.52%
INO Inovio Pharmaceuticals	-3.08%	+4.13%	+22.33%	-3.82%	-48.78%
PMN Promis Neurosciences	-3.25%	-6.17%	-3.65%	+29.42%	+4.91%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATNM Actinium Pharmaceuticals	$1.01 +1.0%	$0.94	$0.74 ▼ $1.80	$31.76M	0.01	147,467 shs	111,591 shs
CBUS Cibus	$1.65 -1.2%	$1.73	$1.09 ▼ $4.19	$126.11M	1.61	433,459 shs	89,727 shs
INO Inovio Pharmaceuticals	$1.29 +2.4%	$1.05	$0.56 ▼ $2.98	$133.38M	1.52	2.54 million shs	1.70 million shs
PMN Promis Neurosciences	$13.78 -1.5%	$13.56	$6.27 ▼ $27.40	$123.58M	-0.23	105,299 shs	51,475 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATNM Actinium Pharmaceuticals	-0.99%	-10.71%	+15.41%	-20.63%	-43.18%
CBUS Cibus	-0.60%	-1.76%	-13.92%	+15.97%	+26.52%
INO Inovio Pharmaceuticals	-3.08%	+4.13%	+22.33%	-3.82%	-48.78%
PMN Promis Neurosciences	-3.25%	-6.17%	-3.65%	+29.42%	+4.91%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATNM Actinium Pharmaceuticals	3.00	Buy	$5.00	395.05% Upside
CBUS Cibus	2.00	Hold	$9.00	445.45% Upside
INO Inovio Pharmaceuticals	2.75	Moderate Buy	$3.17	145.48% Upside
PMN Promis Neurosciences	2.88	Moderate Buy	$34.00	146.73% Upside

Current Analyst Ratings Breakdown

Latest ATNM, PMN, CBUS, and INO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2026	PMN Promis Neurosciences	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$29.00
8/13/2026	INO Inovio Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/13/2026	INO Inovio Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
8/13/2026	INO Inovio Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Positive	$1.80 ➝ $3.00
8/12/2026	INO Inovio Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/3/2026	INO Inovio Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$4.00
7/29/2026	INO Inovio Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/28/2026	PMN Promis Neurosciences	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$35.00 ➝ $69.00
7/27/2026	PMN Promis Neurosciences	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$20.00
7/27/2026	PMN Promis Neurosciences	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$20.00
7/15/2026	PMN Promis Neurosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 8/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATNM Actinium Pharmaceuticals	$35.09M	0.90	N/A	N/A	$1.31 per share	0.77
CBUS Cibus	$3.64M	34.65	N/A	N/A	$0.19 per share	8.68
INO Inovio Pharmaceuticals	N/A	N/A	N/A	N/A	$0.04 per share	N/A
PMN Promis Neurosciences	N/A	N/A	N/A	N/A	$5.51 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATNM Actinium Pharmaceuticals	-$48.82M	$0.36	N/A	N/A	N/A	N/A	-100.85%	-47.89%	N/A
CBUS Cibus	-$127.08M	-$1.65	N/A	N/A	N/A	-2,258.89%	-287.03%	-27.99%	11/12/2026 (Estimated)
INO Inovio Pharmaceuticals	-$84.95M	-$0.91	N/A	N/A	N/A	N/A	-669.94%	-73.97%	11/10/2026 (Estimated)
PMN Promis Neurosciences	-$39.72M	-$8.54	N/A	N/A	N/A	N/A	-143.09%	-109.15%	11/11/2026 (Estimated)

Latest ATNM, PMN, CBUS, and INO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CBUS Cibus	-$0.19	-$0.29	-$0.10	-$0.29	$1.70 million	$0.99 million
8/13/2026	Q2 2026	PMN Promis Neurosciences	-$1.38	-$1.28	+$0.10	-$1.28	N/A	N/A
8/12/2026	Q2 2026	INO Inovio Pharmaceuticals	-$0.2167	-$0.07	+$0.1467	-$0.07	$0.53 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATNM Actinium Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CBUS Cibus	N/A	N/A	N/A	N/A	N/A
INO Inovio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PMN Promis Neurosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATNM Actinium Pharmaceuticals	N/A	10.25	10.25
CBUS Cibus	N/A	1.62	1.62
INO Inovio Pharmaceuticals	N/A	1.00	1.00
PMN Promis Neurosciences	N/A	7.85	7.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATNM Actinium Pharmaceuticals	27.50%
CBUS Cibus	33.81%
INO Inovio Pharmaceuticals	26.79%
PMN Promis Neurosciences	50.13%

Insider Ownership

Company	Insider Ownership
ATNM Actinium Pharmaceuticals	0.60%
CBUS Cibus	29.91%
INO Inovio Pharmaceuticals	1.70%
PMN Promis Neurosciences	1.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATNM Actinium Pharmaceuticals	30	31.44 million	29.32 million	Optionable
CBUS Cibus	48	76.43 million	53.57 million	Optionable
INO Inovio Pharmaceuticals	320	103.40 million	101.64 million	Optionable
PMN Promis Neurosciences	5	8.97 million	8.83 million	Not Optionable

ATNM, PMN, CBUS, and INO Headlines

Recent News About These Companies

Analysts Offer Insights on Healthcare Companies: Hims & Hers Health (HIMS) and ProMIS Neurosciences (PMN)

August 22, 2026 | theglobeandmail.com

PMN Q3 EPS Forecast Boosted by Brookline Capital Markets

August 21, 2026 | americanbankingnews.com

Q3 EPS Estimates for PMN Raised by Brookline Capital Markets

August 19, 2026 | marketbeat.com

Promis Neurosciences (NASDAQ:PMN) Stock Price Expected to Rise, Guggenheim Analyst Says

August 14, 2026 | marketbeat.com

Promis Neurosciences Q2 Earnings Call Highlights

August 13, 2026 | marketbeat.com

Promis Neurosciences (NASDAQ:PMN) Issues Quarterly Earnings Results, Beats Estimates By $0.10 EPS

August 13, 2026 | marketbeat.com

ProMIS Neurosciences Inc.: ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights

August 13, 2026 | finanznachrichten.de

ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights

August 13, 2026 | globenewswire.com

Promis Neurosciences (NASDAQ:PMN) Receives Consensus Rating of "Moderate Buy" from Analysts

August 7, 2026 | marketbeat.com

Promis Neurosciences (PMN) Projected to Post Earnings on Thursday

August 6, 2026 | marketbeat.com

Janus Henderson Group PLC Acquires New Position in Promis Neurosciences $PMN

August 4, 2026 | marketbeat.com

Vertex Pharmaceuticals Inc (VRTX) (Q2 2026) Earnings Call Highlights: Revenue Surges 12% to $3.3 Billion, Driven by CF Portfolio and New Product Momentum

August 4, 2026 | gurufocus.com

ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026

August 3, 2026 | globenewswire.com

ADAR1 Capital Management LLC Buys Shares of 95,350 Promis Neurosciences $PMN

July 30, 2026 | marketbeat.com

Promis Neurosciences (NASDAQ:PMN) Upgraded at Chardan Capital

July 29, 2026 | marketbeat.com

Yu Fan Buys New Stake in Promis Neurosciences $PMN

July 29, 2026 | marketbeat.com

Promis Neurosciences $PMN Stock Holdings Boosted by Ally Bridge Group NY LLC

July 29, 2026 | marketbeat.com

Small-Cap ProMIS Neurosciences Says Lead Drug Shows Encouraging Action in Early Alzheimer's Study

July 28, 2026 | benzinga.com

ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial

July 28, 2026 | markets.businessinsider.com

ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer's Disease Trial

July 28, 2026 | globenewswire.com

ProMIS Neurosciences Inc.: ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer's Disease

July 27, 2026 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATNM, PMN, CBUS, and INO Company Descriptions

Actinium Pharmaceuticals NYSE:ATNM

$1.01 +0.01 (+1.00%)

As of 04:00 PM Eastern

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

Cibus NASDAQ:CBUS

$1.65 -0.02 (-1.20%)

As of 04:00 PM Eastern

Cibus, Inc., a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. Cibus, Inc. is based in San Diego, California.

Inovio Pharmaceuticals NASDAQ:INO

$1.29 +0.03 (+2.38%)

As of 04:00 PM Eastern

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Promis Neurosciences NASDAQ:PMN

$13.78 -0.21 (-1.50%)

As of 04:00 PM Eastern

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATNM, PMN, CBUS, and INO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATNM, PMN, CBUS, and INO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATNM, PMN, CBUS, and INO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATNM, PMN, CBUS, and INO Company Descriptions

Actinium Pharmaceuticals NYSE:ATNM

Cibus NASDAQ:CBUS

Inovio Pharmaceuticals NASDAQ:INO

Promis Neurosciences NASDAQ:PMN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATNM, PMN, CBUS, and INO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATNM, PMN, CBUS, and INO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATNM, PMN, CBUS, and INO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATNM, PMN, CBUS, and INO Company Descriptions

Actinium Pharmaceuticals NYSE:ATNM

Cibus NASDAQ:CBUS

Inovio Pharmaceuticals NASDAQ:INO

Promis Neurosciences NASDAQ:PMN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools